Researchers create new compound to potentially treat negative and positive symptoms of schizophrenia
We often think about diseases in terms of the symptoms they present. A cold might give you the sniffles or even GI distress, while malaria can give you fever, chills, or nausea, for example. These ...
Rallybio begins Phase 2 trial for FNAIT prevention therapy
NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
No serious side effects or discomfort observed Final safety and absorption data expected in March 2025SARASOTA, FL, Feb. 11, 2025 (GLOBE ...
Rani Therapeutics reports positive obesity treatment study
SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...
manilatimes14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and ...
Nasdaq14d
Y-mAbs Presents GD2-SADA Pharmacokinetics Data At SNMMI And ACNM Annual Meeting
The poster, titled "Preclinical and Translational Pharmacokinetics of GD2-SADA ... regimen for the ongoing first-in-human or FIH Phase 1 Trial or Trial 1001. Y-mAbs is focused on advancing GD2 ...
Nasdaq14d
Y-mAbs Therapeutics Presents Preclinical Data on GD2-SADA at SNMMI/ACNM Annual Meeting
The preclinical and translational pharmacokinetics data of GD2-SADA was presented at the SNMMI and ACNM Annual Meeting in Anaheim, California. Trial 1001 aims to refine the human pharmacokinetics ...
Yahoo Finance14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and ...
Morningstar14d
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting
GD2-SADA PRIT with 177Lutetium-DOTA has demonstrated robust anti-tumor efficacy in preclinical studies and is currently being investigated in adults and adolescents with GD2-expressing solid ...
PipelineReview.com15d
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
The trial will enroll a total of 130 patients and ... further underlining its potential efficacy. Preclinical analysis including safety, efficacy and pharmacokinetics demonstrated that TUB-030 has a ...